LABELS · 535caad0-ae02-4ceb-b4d1-192222633719

Cefepime

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-25
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Cefepime Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: pneumonia ( 1.1 ); empiric therapy for febrile neutropenic patients ( 1.2 ); uncomplicated and complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Full extracted label fields

application numbers

NDA050817

boxed warning exact

brand names

Cefepime

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be5f8ca6-7232-423a-a2d5-cccb7abe7921

generic names

CEFEPIME

535caad0-ae02-4ceb-b4d1-192222633719

indications and usage exact

1 INDICATIONS AND USAGE Cefepime Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: pneumonia ( 1.1 ); empiric therapy for febrile neutropenic patients ( 1.2 ); uncomplicated and complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

indications and usage tables exact

is original packager

true

manufacturer names

Baxter Healthcare Corporation

matched search terms

malignancy

package ndcs

0338-1301-41
0338-1301-48

product ndcs

0338-1301

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1665088
1665093

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 687
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Cefepime Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: pneumonia ( 1.1 ); empiric therapy for febrile neutropenic patients ( 1.2 ); uncomplicated and complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent inf
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 0

current approval status

not_reconciled

duplicate text group

dup-2f6537e362964aef956f

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-d9e79181343f1ddebe25

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 85
end exclusive: true
exact text: is a cephalosporin antibacterial indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 43

qualifier mentions

context exact
icated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ).
kind
biomarker
polarity
not_inferred
span
end
482
end exclusive
true
exact text
metronidazole) ( 1
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
464
context exact
s ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ).
kind
regimen
polarity
not_inferred
span
end
482
end exclusive
true
exact text
in combination with metronidazole) ( 1
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
444

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 487
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Cefepime Injection is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: pneumonia ( 1.1 ); empiric therapy for febrile neutropenic patients ( 1.2 ); uncomplicated and complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ).
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 958
end exclusive: true
exact text: nd complicated urinary tract infections ( 1.3 ); uncomplicated skin and skin structure infections ( 1.4 ); and complicated intra-abdominal infections (used in combination with metronidazole) ( 1.5 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aerugin
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 288

current approval status

not_reconciled

duplicate text group

dup-9dabc9049986d6be5da4

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-8dece7fe63f909c3f1d2

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 758
end exclusive: true
exact text: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 488

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 966
end exclusive: true
exact text: ffectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Kle
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 559

current approval status

not_reconciled

duplicate text group

dup-da1c3c4de40eb23bbc7c

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-d6263b2b4af5d830d9e7

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 766
end exclusive: true
exact text: ( 1.6 )
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 759

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1210
end exclusive: true
exact text: ness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infectio
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 567

current approval status

not_reconciled

duplicate text group

dup-adfe51100f910b7ca178

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-946a64cc0a6abe20de43

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 812
end exclusive: true
exact text: is indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 800

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1010
end exclusive: true
exact text: 1.1 Pneumonia Cefepime Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 767

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1365
end exclusive: true
exact text: d for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 811

current approval status

not_reconciled

duplicate text group

dup-0479683d8031358089a4

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-0ffffec64adee5052a25

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 1110
end exclusive: true
exact text: is indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1098

qualifier mentions

context exact
Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients.
kind
regimen
polarity
not_inferred
span
end
1164
end exclusive
true
exact text
as monotherapy is indicated for empiric treatment of febrile neutropenic patients
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
1083

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1165
end exclusive: true
exact text: 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1011

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1654
end exclusive: true
exact text: bsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyeloneph
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 966

current approval status

not_reconciled

duplicate text group

dup-f57c1bbb0d94b81c6b5a

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-0e39c7ca1ae5d6901297

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1454
end exclusive: true
exact text: In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1166

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1774
end exclusive: true
exact text: t bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephri
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1255

current approval status

not_reconciled

duplicate text group

dup-72f4385c1d2e862a442c

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-d608977550171622e0f4

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1574
end exclusive: true
exact text: Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ].
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1455

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2258
end exclusive: true
exact text: re or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [ see Clinical Studies (14) ]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isol
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1375

current approval status

not_reconciled

duplicate text group

dup-1d49028217a7ba325503

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-06e4050c3d04cdc204b0

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 1692
end exclusive: true
exact text: is indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1680

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2058
end exclusive: true
exact text: 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime Injection is indicated for uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1575

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2496
end exclusive: true
exact text: e, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans gro
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 1859

current approval status

not_reconciled

duplicate text group

dup-a04fe913e545f3addb85

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-7ce3d89e5210dff3d0b4

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 2143
end exclusive: true
exact text: is indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2131

qualifier mentions

context exact
skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes .
kind
biomarker
polarity
not_inferred
span
end
2273
end exclusive
true
exact text
methicillin-susceptible isolates only) or S
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
2230

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2296
end exclusive: true
exact text: 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes .
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2059

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · positive indication candidate

application numbers

NDA050817

brand names

Cefepime

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2835
end exclusive: true
exact text: ure Infections Cefepime Injection is indicated for uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . 1.5 Complicated Intra-abdominal Infections Cefepime Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or p
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2097

current approval status

not_reconciled

duplicate text group

dup-329eb8ed7ce0fa5bb2b4

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-4b2df90425e7d6561699

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

end: 2371
end exclusive: true
exact text: is indicated
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2359

qualifier mentions

context exact
icated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebs
kind
biomarker
polarity
not_inferred
span
end
2482
end exclusive
true
exact text
metronidazole) caused by Escherichia coli
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
2441
context exact
indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ].
kind
regimen
polarity
not_inferred
span
end
2600
end exclusive
true
exact text
in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fra
label id
535caad0-ae02-4ceb-b4d1-192222633719
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start
2421

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2635
end exclusive: true
exact text: 1.5 Complicated Intra-abdominal Infections Cefepime Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ].
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2297

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3128
end exclusive: true
exact text: with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14) ]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibilit
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2436

current approval status

not_reconciled

duplicate text group

dup-76f3268d5c91cbd4f4ee

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-a7e1837f55e5d0c18afe

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2928
end exclusive: true
exact text: 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2636

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3190
end exclusive: true
exact text: of Cefepime Injection and other antibacterial drugs, Cefepime Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2729

current approval status

not_reconciled

duplicate text group

dup-c570a6872d6296a59db2

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-0506c9ac1ca303bb68e5

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 3062
end exclusive: true
exact text: When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2929

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA050817

brand names

Cefepime

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3190
end exclusive: true
exact text: roven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 2863

current approval status

not_reconciled

duplicate text group

dup-b69919a6f1b057852e53

extraction review status

automated_candidate_pending_source_review

generic names

CEFEPIME

ind-span-4bcb6e42b683218e9d09

label id

535caad0-ae02-4ceb-b4d1-192222633719

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 3190
end exclusive: true
exact text: In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
label id: 535caad0-ae02-4ceb-b4d1-192222633719
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 9fb5b06117ccb2c0999edb294bae0c873caee7eafca2ddad6f1db680068fcef6
start: 3063

source url

https://api.fda.gov/drug/label.json?search=id%3A%22535caad0-ae02-4ceb-b4d1-192222633719%22

spl effective date

2026-06-25

spl set id

be5f8ca6-7232-423a-a2d5-cccb7abe7921

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice